BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31709477)

  • 21. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.
    Wang GY; Zhang SL; Wang XR; Feng M; Li C; An Y; Li XF; Wang LZ; Wang CH; Wang YF; Yang R; Yan HM; Wang GC; Lu X; Liu X; Zhu P; Chen LN; Jin HT; Liu JT; Guo HF; Chen HY; Xie JL; Wei P; Wang JX; Liu XY; Sun L; Cui LF; Shu R; Liu BL; Yu P; Zhang ZL; Li GT; Li ZB; Yang J; Li JF; Jia B; Zhang FX; Tao JM; Lin JY; Wei MQ; Liu XM; Ke D; Hu SX; Ye C; Han SL; Yang XY; Li H; Huang CB; Gao M; Lai B; Cheng YJ; Li XF; Song LJ; Yu XX; Wang AX; Wu LJ; Wang YH; He L; Sun WW; Gong L; Wang XY; Wang Y; Zhao Y; Li XX; Wang Y; Zhang Y; Su Y; Zhang CF; Mu R; Li ZG
    Clin Rheumatol; 2015 Feb; 34(2):221-30. PubMed ID: 25413735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.
    Versteeg GA; Steunebrink LMM; Vonkeman HE; Ten Klooster PM; van der Bijl AE; van de Laar MAFJ
    Clin Rheumatol; 2018 May; 37(5):1189-1197. PubMed ID: 29388086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study.
    Cai YM; Li R; Ye H; He J; Sun XL; Jin JY; Liu JJ; Gan YZ; You XJ; Xu J; Shi LJ; Cheng G; Wang QW; Li ZG
    Chin Med J (Engl); 2020 Jun; 133(12):1397-1403. PubMed ID: 32496302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
    Kuusalo LA; Puolakka KT; Kautiainen H; Alasaarela EM; Hannonen PJ; Julkunen HA; Kaipiainen-Seppänen OA; Korpela MM; Möttönen TT; Paimela LH; Peltomaa RL; Yli-Kerttula TK; Leirisalo-Repo M; Rantalaiho VM;
    Clin Exp Rheumatol; 2016; 34(6):1038-1044. PubMed ID: 27494516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
    Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
    Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden.
    Einarsson JT; Willim M; Ernestam S; Saxne T; Geborek P; Kapetanovic MC
    Rheumatology (Oxford); 2019 Feb; 58(2):227-236. PubMed ID: 29538755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study.
    O'Connor A; Thorne C; Kang H; Tin D; Pope JE
    BMC Musculoskelet Disord; 2016 Aug; 17(1):364. PubMed ID: 27558249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
    Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
    J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.
    Paulshus Sundlisæter N; Olsen IC; Aga AB; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
    Rheumatology (Oxford); 2018 Nov; 57(11):2022-2031. PubMed ID: 30053199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
    Pomirleanu C; Ancuta C; Miu S; Chirieac R
    Clin Rheumatol; 2013 May; 32(5):665-70. PubMed ID: 23292520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
    Källmark H; Einarsson JT; Nilsson JÅ; Olofsson T; Saxne T; Geborek P; C Kapetanovic M
    Arthritis Rheumatol; 2021 Jul; 73(7):1135-1144. PubMed ID: 33682353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study.
    Tam LH; Shang Q; Li EK; Wong PC; Kwok KY; Kun EW; Yim IC; Lee VK; Yip RM; Pang SH; Lao VW; Mak QW; Cheng IT; Lau XS; Li TK; Zhu TY; Lee AP; Tam LS
    J Rheumatol; 2018 Aug; 45(9):1229-1239. PubMed ID: 29764965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
    Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
    J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DAS28-ESR and DAS28-CRP - are they Interchangeable in Measuring the Activity of Rheumatoid Arthritis in Response to Treatment with Biological Agents?
    Shivacheva TK
    Folia Med (Plovdiv); 2020 Mar; 62(1):46-51. PubMed ID: 32337896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.